Expertise in
5
conditions

Satoshi Oizumi

Sapporo, JP 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
5
conditions
Sapporo, JP 

Overview

Satoshi Oizumi practices practicing medicine in Sapporo, Japan.

Mr. Oizumi is highly rated in 5 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, Small Cell Lung Cancer (SCLC), and Endoscopy.

He is actively involved in clinical research, co-authoring 101 peer reviewed articles and participating in 2 clinical trials.

Gender

Male

Locations

Sapporo, Japan
Other Locations
Japan
Kikusuicho, Japan
Hidaka, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)
A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)
Enrollment Status: Recruiting
Publish Date: April 03, 2026
Intervention Type: Drug
Study Drug: Repotrectinib
Study Phase: Phase 1/Phase 2
An Adaptive Phase III, Multicenter, Randomized, Open-Label, Controlled Study of M7824 (Bintrafusp Alfa) Versus Pembrolizumab as a First-line Treatment in Patients With PD-L1 Expressing Advanced Non-small Cell Lung Cancer
An Adaptive Phase III, Multicenter, Randomized, Open-Label, Controlled Study of M7824 (Bintrafusp Alfa) Versus Pembrolizumab as a First-line Treatment in Patients With PD-L1 Expressing Advanced Non-small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: April 08, 2025
Intervention Type: Drug
Study Drugs: M7824, Pembrolizumab
Study Phase: Phase 3
View 1 Less Clinical Trial

101 Total Publications

Impact of vulnerability on concurrent chemoradiotherapy outcomes in patients with locally advanced non-small cell lung cancer using an integrated clinical trial database.
Impact of vulnerability on concurrent chemoradiotherapy outcomes in patients with locally advanced non-small cell lung cancer using an integrated clinical trial database.
Journal: Therapeutic advances in medical oncology
Published: October 07, 2025

Frequently Asked Questions about Satoshi Oizumi

Is Satoshi Oizumi a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Satoshi Oizumi is classified as an Elite expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Satoshi Oizumi participate in research or clinical trials?

Yes. Satoshi Oizumi has published 101 articles and abstracts on conditions like Lung Cancer. You can view a list of Satoshi Oizumi's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Oizumi's expertise for a condition
ConditionClose
View All 13 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile